

PHA 5127 Dose Optimization I
Fall 2011
Case Study IV

If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember that attendance is mandatory. Students whose IPEE coincides with the case study lecture are excused.

Problem 1

T.T. (male, 6'3" tall, 111 kg, 24 years old) shows a serum creatinine level of 1.3 mg/dL.

- a) Use the Cockcroft-Gault-Equation to calculate his creatinine clearance and glomerular filtration rate (GFR). Comment on the renal function of T.T.?
- b) Why do we use the creatinine clearance to estimate the GFR?
- c) Drug A shows a plasma protein binding and tissue protein binding of 10% and 95%, respectively. Drug A is eliminated by hepatic (80%) and renal processes (20%). Calculate the total systemic clearance of drug A (in L/h) when administered to T.T. Assume that the drug is neither actively secreted nor reabsorbed.
- d) Graph the plasma-concentration time profile for the first 24 hours when 1000mg of drug A are administered to T.T. via an IV bolus injection. Assume that the drug is immediately distributed throughout the body, crosses membranes easily, and that all elimination processes are first-order processes.

Problem 2

Which properties does a drug need to have in order to demonstrate the following? Explain briefly.

- a) Active tubular secretion
- b) Glomerular secretion
- c) Passive tubular reabsorption

Problem 3

Assume that drug B is only cleared by metabolism processes. For a fixed VD, sketch graphs describing the relationship between the following PK metrics for a) non-saturable metabolism enzymes (linear PK) and b) saturable metabolism enzymes (non-linear PK).

- I. dX/dt (elimination rate) vs. C (plasma concentration)
- II. CL vs. Dose
- III. AUC vs. Dose